BackgroundCheck.run
Search For

Gary A Decrescenzo, 656135 Westwood Ct, Parkville, MO 64152

Known as:
Gary Anthony Decrescenzo Gary Anthony Crescenzo Gar Decrescenzo Gary Anthony Z

Gary Decrescenzo Phones & Addresses

Parkville, MO   

O Fallon, MO   

Saint Charles, MO   

Melbourne, FL   

Orlando, FL   

Get Report
Control this profile

Mentions for Gary A Decrescenzo

Gary Decrescenzo resumes & CV records

Resumes

Gary Decrescenzo Photo 9

Senior Vice President, Pharmaceutical Research And Development At Confluence

Location:
Kansas City, MO
Industry:
Pharmaceuticals
Work:
Confluence Discovery Technologies A Wholly Owned Subsidiary of Aclaris Therapeutics
Senior Vice President, Pharmaceutical Research and Development at Confluence Biomed Valley Discoveries Sep 2010 - Aug 2018
Executive Director, Head of Chemistry Externaleyes Jul 2010 - Dec 2014
President Pfizer Research and Development Mar 2008 - May 2010
Senior Director World Wide Medicinal Chemistry Pfizer Research and Development Mar 2006 - Mar 2008
Executive Director of Inflammation Pfizer Apr 2003 - Mar 2006
Executive Director of Chemistry Pharmacia Corporation/Searle Pharmaceuticals 1993 - 2003
Director of Chemistry G D Searle 1990 - 2000
Chemistry Director Monsanto Company 1984 - 1993
Scientist
Education:
University of Central Florida 1979 - 1984
Melbourne High School
Skills:
Life Sciences, Biotechnology, Drug Discovery, Drug Development, Pharmaceutical Industry, Technology Transfer, Biochemistry, Medicinal Chemistry, Hplc, Chemistry
Gary Decrescenzo Photo 10

Senior Vice President Research And Pharmaceutical Development

Location:
Kansas City, MO
Work:
Aclaris Therapeutics, Inc.
Senior Vice President Research and Pharmaceutical Development
Gary Decrescenzo Photo 11

Gary Decrescenzo

Publications & IP owners

Us Patents

Oral Compositions Of Mk2 Pathway Inhibitor For Treatment Of Immune Conditions

US Patent:
2021033, Nov 4, 2021
Filed:
Mar 26, 2021
Appl. No.:
17/214532
Inventors:
- Wayne PA, US
Joseph MONAHAN - Eureka MO, US
Edward HELLRIEGEL - Barto PA, US
David GORDON - Ardmore PA, US
Heidi HOPE - St. Louis MO, US
John Robert SPRINGER - Wentzville MO, US
Gary A. DECRESCENZO - Parkville MO, US
International Classification:
A61K 31/506
A61K 9/00
A61K 45/06
A61K 9/20
A61P 37/06
Abstract:
The present disclosure relates to oral compositions of Compound I or a derivative thereof. Methods of use for treating an inflammatory condition are also disclosed.

Methods And Compositions For Treating Non-Erk Mapk Pathway Inhibitor-Resistant Cancers

US Patent:
2021003, Feb 11, 2021
Filed:
Oct 23, 2020
Appl. No.:
17/078255
Inventors:
- Kansas City MO, US
Dean Welsch - Parkville MO, US
Gary DeCrescenzo - Parkville MO, US
Jeffrey James Roix - Boston MA, US
International Classification:
A61K 31/4439
A61K 45/06
A61K 31/506
A61K 31/519
G01N 33/574
C12Q 1/6886
Abstract:
The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.

Cancer Treatments Using Combinations Of Cdk And Erk Inhibitors

US Patent:
2020029, Sep 24, 2020
Filed:
Apr 23, 2020
Appl. No.:
16/856849
Inventors:
- Kansas City MO, US
Dean Welsch - Parkville MO, US
Gary DeCrescenzo - Parkville MO, US
Jeffrey James Roix - Boston MA, US
International Classification:
A61K 31/519
A61K 31/4439
A61K 31/506
A61K 45/06
C07D 401/04
Abstract:
The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.

Anti-Cd276 Antibodies (B7H3)

US Patent:
2020019, Jun 25, 2020
Filed:
Mar 9, 2020
Appl. No.:
16/812980
Inventors:
- Bethesda MD, US
- Kansas City MO, US
Bradley St. Croix - Frederick MD, US
Steven Seaman - Martinsburg WV, US
Saurabh Saha - Wellesley Hills MA, US
Xiaoyan Michelle Zhang - Lexington MA, US
Gary A. DeCrescenzo - Parkville MO, US
Dean Welsch - Parkville MO, US
International Classification:
C07K 16/30
G01N 33/574
A61P 35/00
A61K 47/68
C07K 16/28
A61K 39/395
Abstract:
Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.

Methods And Compositions For Treating Non-Erk Mapk Pathway Inhibitor-Resistant Cancers

US Patent:
2019020, Jul 4, 2019
Filed:
May 22, 2017
Appl. No.:
16/302955
Inventors:
- Kansas City MO, US
Dean Welsch - Parkville MO, US
Gary Decrescenzo - Parkville MO, US
Jeffrey Roix - Boston MA, US
International Classification:
A61K 31/4439
A61K 31/506
A61K 45/06
A61K 31/519
G01N 33/574
C12Q 1/6886
Abstract:
The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.

Anti-Cd276 Antibodies (B7H3)

US Patent:
2018018, Jul 5, 2018
Filed:
Sep 16, 2015
Appl. No.:
15/512000
Inventors:
- Bethesda MD, US
- Kansas City MO, US
Bradley St. Croix - Frederick MD, US
Steven Seaman - Martinsburg WV, US
Saurabh Saha - Wellesley Hills MA, US
Xiaoyan Michelle Zhang - Lexington MA, US
Gary A. DeCrescenzo - Parkville MO, US
Dean Welsch - Parkville MO, US
International Classification:
C07K 16/30
C07K 16/28
A61K 47/68
A61P 35/00
G01N 33/574
Abstract:
Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric N antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.

Methods And Compositions For Treating Non-Erk Mapk Pathway Inhibitor-Resistant Cancers

US Patent:
2018010, Apr 19, 2018
Filed:
Oct 30, 2017
Appl. No.:
15/797593
Inventors:
- Kansas City MO, US
Dean Welsch - Parkville MO, US
Gary DeCrescenzo - Parkville MO, US
Jeffrey James Roix - Boston MA, US
International Classification:
A61K 31/4439
A61K 31/506
A61K 45/06
A61K 31/519
C12Q 1/6886
G01N 33/574
Abstract:
The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.

Tem8 Antibodies And Their Use In Treatment And Detection Of Tumors

US Patent:
2017035, Dec 14, 2017
Filed:
Aug 17, 2017
Appl. No.:
15/680177
Inventors:
- Bethesda MD, US
- Kansas City MO, US
Brad St. Croix - Frederick MD, US
Enrique Zudaire - Germantown MD, US
Saurabh Saha - Wellesley Hills MA, US
Xiaoyan Michelle Zhang - Lexington MA, US
Gary Decrescenzo - Parkville MO, US
Dean Welsch - Parkville MO, US
International Classification:
C07K 16/28
G01N 33/574
A61K 47/68
C07K 16/30
A61K 45/06
A61K 39/395
A61K 9/00
C07K 14/725
A61K 49/16
A61K 39/00
Abstract:
Antibodies that specifically bind TEM8 protein, conjugates thereof, and their use, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.

Possible Relatives

Edward T Decrescenzo  Frank Decrescenzo  James A Decrescenzo  John Decrescenzo  Joseph F Decrescenzo  Kristina Decrescenzo  Marie M Decrescenzo  Gary R Johnson  Gary Stamps  Gary H Stancil 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.